

Lumixyl™

Clinical Summary

Beauty through Science

Summary of Current Clinical and Scientific Evidence for Lumixyl™

Introduction

Skin Brightening products are used extensively with patients for a wide range of conditions. The use of skin brightening products are mainly for aesthetic reasons yet these products have historically only been available on prescription or restricted by the relevant Governmental authorities due to their concerns over side effects of these acid based treatments.

Lumixyl™ offers clinically proven effective technology that has a unique mode of action. This makes it safe for long term as well as short term usage. Lumixyl™ is used to treat a range of skin conditions, such as;



Age or 'Liver' spots also known as Solar Lentigos



Melasma




Post inflammatory Hyperpigmentation

All the above conditions are caused by the over production of melanin in the skin.

In-Vitro Data

Lumixyl™ inhibits the production of tyrosinase, which is a precursor in the production of melanin. The active ingredient in Lumixyl™ is Decapeptide-12, which has been found to be an effective inhibitor of tyrosinase. The mode of action and safety profiles were published in the Journal of Investigative Dermatology in 2009¹. The study found that Decapeptide-12 inhibits the over production of melanin by 40%.





In-Vivo Testing

The results of a small pilot clinical study were also published in the Journal of Drugs in Dermatology in 2009². The study was a split faced, double blind, randomized and placebo controlled evaluation of a unique Oligopeptide for the treatment of recalcitrant melasma.

Method

Both Decapeptide-12 and the placebo were applied to the same patient. The patient used the treatments over a period of 16 weeks. Five patients were Fitzpatrick skin type IV, who had failed outcomes using other treatments for melasma. Changes in the melasma were measured using photography and peer reviewed evaluation. In addition, patient satisfaction was measured over the duration of the trial.

Results

The treatment was well tolerated by all the patients with no signs of skin sensitivity or irritation. All five patients showed a significant improvement in their melasma and overall facial aesthetics compared to the placebo. In addition, patient satisfaction was highly rated.

Conclusion

Lumixyl™ and its active ingredient Decapapetide-12, have proven to have a strong inhibitory effect on the production of melanin. This unique way of treating hyperpigmentation provides an efficacious way to stop the over production of melanin and hence minimise hyperpigmentation. In studies carried out to date there are no toxicity issues, long term use of this innovative peptide should allow patients to treat their hyperpigmentation on an on-going basis.

Further studies are currently underway in different skin types and conditions.

If you would like more information please contact info@silderm.com or call the customer care line on **0844 544 9969**.

1 J Invest Dermatol. 2009 Sep;129(9):2242-9
 2 J Drugs Dermatol. 2009 Aug;8(8):732-5

